A Double-Blind, Randomised, Placebo-Controlled, Escalating, Multiple Dose Study in to Assess the Safety, Tolerability and Pharmacodynamic Effects of Birch-SPIRE
Phase of Trial: Phase II
Latest Information Update: 11 Nov 2016
At a glance
- Drugs Birch pollen allergy immunotherapy (Primary)
- Indications Rhinitis
- Focus Adverse reactions
- Sponsors Circassia
- 07 Nov 2016 Status changed from active, no longer recruiting to completed.
- 08 Feb 2016 Planned primary completion date changed from 1 Jan 2016 to 1 Jul 2016 as per ClinicalTrials.gov record.
- 26 Oct 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.